查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541359

2024-2032 年淋巴瘤治療市場報告（按類型、測試類型、藥物和地區）

Lymphoma Treatment Market Report by Type, Test Type, Drug, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球淋巴瘤治療市場規模達133億美元。

淋巴瘤是指以淋巴系統中異常惡性細胞快速發展為特徵的一類癌症。它通常以淋巴結、脾臟、胸腺和骨髓中的白血球 (WBC) 或淋巴細胞為目標，損害身體的免疫反應。結果，患者出現淋巴結腫脹、高燒、體重減輕、呼吸困難和疲倦。一些常用的淋巴瘤治療方法包括放射線、化療和單株抗體治療、主動監測、骨髓移植和免疫療法藥物。這些療法廣泛用於治療霍奇金淋巴瘤和非何杰金氏淋巴瘤。

全球非何杰金氏淋巴瘤盛行率的不斷上升是推動市場成長的關鍵因素之一。此外，老年人口的增加也推動了市場的成長，老年人口更容易罹患此類疾病。與此一致的是，大眾汽車對淋巴瘤可用診斷技術和治療替代方案的認知不斷提高，也為市場創造了積極的前景。醫院和其他診斷中心正在使用創新的測試和影像技術，例如電腦斷層掃描（CT）、磁振造影（MRI）和正子斷層掃描（PET）掃描，以準確識別癌細胞並及時治療。此外，各種技術進步，包括創新免疫檢查點抑制劑的開發，可阻止蛋白質結合在一起並增強 T 細胞對抗癌細胞的反應強度，都有助於市場成長。其他因素，包括腫瘤學領域廣泛的研發（R&D）活動，以及醫療保健基礎設施的整體改善，預計將進一步推動市場發展。

本報告回答的關鍵問題：

  • 迄今為止，全球淋巴瘤治療市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球淋巴瘤治療市場有何影響？
  • 主要區域市場有哪些？
  • 依類型分類市場是怎麼樣的？
  • 根據測試類型，市場的細分是什麼？
  • 基於藥物的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球淋巴瘤治療市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球淋巴瘤治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 霍奇金淋巴瘤
    • 市場趨勢
    • 市場預測
  • 非何杰金氏淋巴瘤
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按測試類型

  • 化療
    • 市場趨勢
    • 市場預測
  • 放射治療
    • 市場趨勢
    • 市場預測
  • 免疫療法
    • 市場趨勢
    • 市場預測
  • 標靶治療
    • 市場趨勢
    • 市場預測
  • 生物療法
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依藥品分類

  • 阿德塞特里斯
    • 市場趨勢
    • 市場預測
  • 利妥昔單抗
    • 市場趨勢
    • 市場預測
  • 奧狄沃
    • 市場趨勢
    • 市場預測
  • 伊布維卡
    • 市場趨勢
    • 市場預測
  • 可瑞達
    • 市場趨勢
    • 市場預測
  • 來那度胺
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Merck & Co. Inc.
    • Novartis International AG
    • Spectrum Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Ltd.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A3385

The global lymphoma treatment market size reached US$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.

Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It usually targets the white blood cells (WBCs), or lymphocytes, in lymph nodes, spleen, thymus and bone marrow and impairs the immune response of the body. As a result, the patient develops swelling in the lymph nodes, high fever, weight loss, dyspnea and fatigue. Some of the commonly used lymphoma therapeutics include radiation, chemo and monoclonal antibody therapy, active surveillance, bone marrow transplant and immunotherapy drugs. These therapeutics are widely used for the treatment of both Hodgkin and non-Hodgkin lymphoma.

The increasing prevalence of non-Hodgkin lymphoma across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness among the masses regarding the available diagnostic technologies and treatment alternatives for lymphoma is also creating a positive outlook for the market. Hospitals and other diagnostic centers are using innovative tests and imaging technologies, such as computed tomography (CT), Magnetic Resonance Imaging (MRI) and positron emission tomography (PET) scans, for accurate identification of the cancer cells and timely treatment. Additionally, various technological advancements, including the development of innovative immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, are contributing to the market growth. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global lymphoma treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, test type and drug.

Breakup by Type:

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Breakup by Test Type:

Chemotherapy

Radiation Therapy

Immunotherapy

Targeted Therapy

Biologic Therapy

Others

Breakup by Drug:

Adcetris

Rituxan

Opdivo

Imbruvica

Keytruda

Revlimid

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global lymphoma treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global lymphoma treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the test type?
  • What is the breakup of the market based on the drug?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global lymphoma treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lymphoma Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hodgkin Lymphoma
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Hodgkin Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Test Type

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiation Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Targeted Therapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Biologic Therapy
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Drug

  • 8.1 Adcetris
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Rituxan
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Opdivo
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Imbruvica
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Keytruda
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Revlimid
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Eli Lilly and Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 F. Hoffmann-La Roche Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Johnson & Johnson Services, Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis International AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Spectrum Pharmaceuticals, Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Lymphoma Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Lymphoma Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Lymphoma Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Lymphoma Treatment Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Lymphoma Treatment Market: Breakup by Test Type (in %), 2023
  • Figure 6: Global: Lymphoma Treatment Market: Breakup by Drug (in %), 2023
  • Figure 7: Global: Lymphoma Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Lymphoma Treatment (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Lymphoma Treatment (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Lymphoma Treatment (Non-Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Lymphoma Treatment (Non-Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Lymphoma Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Lymphoma Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Lymphoma Treatment (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Lymphoma Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Lymphoma Treatment (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Lymphoma Treatment (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Lymphoma Treatment (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Lymphoma Treatment (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Lymphoma Treatment (Biologic Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Lymphoma Treatment (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Lymphoma Treatment (Other Test Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Lymphoma Treatment (Other Test Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Lymphoma Treatment (Adcetris) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Lymphoma Treatment (Adcetris) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Lymphoma Treatment (Rituxan) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Lymphoma Treatment (Rituxan) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Lymphoma Treatment (Opdivo) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Lymphoma Treatment (Opdivo) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Lymphoma Treatment (Imbruvica) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Lymphoma Treatment (Imbruvica) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Lymphoma Treatment (Keytruda) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Lymphoma Treatment (Keytruda) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Lymphoma Treatment (Revlimid) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Lymphoma Treatment (Revlimid) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Lymphoma Treatment (Other Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Lymphoma Treatment (Other Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: North America: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: North America: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: United States: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: United States: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Canada: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Canada: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Asia-Pacific: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Asia-Pacific: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: China: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: China: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Japan: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Japan: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: India: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: India: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: South Korea: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: South Korea: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Australia: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Australia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Indonesia: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Indonesia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Europe: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Europe: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Germany: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Germany: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: France: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: France: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: United Kingdom: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: United Kingdom: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Italy: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Italy: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Spain: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Spain: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Russia: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Russia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Latin America: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Latin America: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Brazil: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Brazil: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Mexico: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Mexico: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Middle East and Africa: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Middle East and Africa: Lymphoma Treatment Market: Breakup by Country (in %), 2023
  • Figure 86: Middle East and Africa: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Global: Lymphoma Treatment Industry: SWOT Analysis
  • Figure 88: Global: Lymphoma Treatment Industry: Value Chain Analysis
  • Figure 89: Global: Lymphoma Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Lymphoma Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Lymphoma Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Lymphoma Treatment Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 4: Global: Lymphoma Treatment Market Forecast: Breakup by Drug (in Million US$), 2024-2032
  • Table 5: Global: Lymphoma Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Lymphoma Treatment Market: Competitive Structure
  • Table 7: Global: Lymphoma Treatment Market: Key Players